Role of Hydroxyurea in Patients of Beta Thalassemia Majo

Objective: To study the role of Hydroxyurea in patients suffering from β-thalassemia major.
 Study Design: Prospective longitudinal study.
 Place and Duration Study: Department Paediatrics, Combined Military Hospital, Malir Cantt, Karachi Pakistan, Nov 2019 to Oct 2020.
 Methodology: Data 73 beta-thalassemia major was collected using a structured questionnaire containing inquiries about basic socio-demographic details, disease history, laboratory reports particulars former treatment regimens. administered, its effects were noted among subjects regarding frequency transfusion, haemoglobin levels severity clinical symptoms.
 Results: The mean age 9.15±3.99 years, most (56.14%) boys. preintervention (before administration Hydroxyurea) Hemoglobin (Hb), corpuscular volume (MCV), concentration (MCHC), serum ferritin unremarkable when compared postintervention levels. However, significant difference observed HbF In addition, an encouraging decrease reported self-rated (using VAS) symptoms such as fatigue (p<0.05), weakness (p>0.05), shortness breath (p>0.05). transfusion interval significantly reduced (p<0.05).
 Conclusion: After carefully considering results, it can be concluded that plays positive brings improvement Keywords: Fetal hemoglobin, Genetic disease, Hydroxyurea, Thalassemia major.